New

Ask Wove anything about tariffs.

Try Tariff Assistant

3-Quinuclidinol

Heterocyclic compounds with nitrogen hetero-atom(s) only. > Compounds containing an unfused imidazole ring (whether or not hydrogenated) in the structure: > 3-Quinuclidinol > 3-Quinuclidinol > 3-Quinuclidinol

Duty Rate (from China)

0%
MFN TariffFree
Total Effective Rate0%

Products classified under Tariff item 2933.35.00

3-Hydroxyquinuclidine

3-Hydroxyquinuclidine, also known as 3-quinuclidinol, is a bicyclic alcohol containing a nitrogen hetero-atom in a hydrogenated pyridine ring. It is a separate chemically defined organic compound, fitting the scope of Chapter 29. It is classifiable under tariff item 2933.35.00 as it matches the specific description of 3-quinuclidinol.

3-Quinuclidinol

3-Quinuclidinol is a bicyclic heterocyclic alcohol with a nitrogen hetero-atom in a hydrogenated pyridine ring. It is a separate chemically defined organic compound, falling under Chapter 29. It is specifically named in tariff item 2933.35.00, making it directly classifiable there.

3-Quinuclidinol Hydrochloride

3-Quinuclidinol hydrochloride is the salt form of 3-quinuclidinol, formed by the addition of hydrochloric acid. Per Chapter 29 Note 5, inorganic salts of organic compounds are classified with the parent organic compound. Thus, it falls under tariff item 2933.35.00 as a salt of 3-quinuclidinol.

(R)-3-Quinuclidinol

(R)-3-Quinuclidinol is the enantiomerically pure R-form of 3-quinuclidinol, a bicyclic alcohol with a nitrogen hetero-atom. As a stereoisomer of the named compound, it is covered by Chapter 29 Note 1(b) for mixtures of isomers, and here as a single isomer, it falls under tariff item 2933.35.00. It is used as an intermediate in pharmaceutical synthesis.

(S)-3-Quinuclidinol

(S)-3-Quinuclidinol is the S-enantiomer of 3-quinuclidinol, a nitrogen-containing bicyclic alcohol. It is a separate chemically defined organic compound, and as a stereoisomer of 3-quinuclidinol, it falls under tariff item 2933.35.00. It is used in the synthesis of CNS-active pharmaceutical intermediates.